Literature DB >> 10779385

Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies.

P L Prather1, N A Martin, C S Breivogel, S R Childers.   

Abstract

Previous studies had shown that the amplification factors for cannabinoid receptors, defined as the number of total G proteins activated per occupied receptor, differs between several rat brain regions. In this study, we sought to determine which specific Gi/Go(alpha) subunits were activated by CB1 receptors in several rat brain regions and if this coupling might explain the regional differences in receptor/G protein amplification factors. Furthermore, we examined whether cannabinoid agonists might activate different subtypes of G(alpha) subunits with varying degrees of efficacy and/or potency. Activation of specific G proteins by cannabinoid receptors was evaluated by the ability of the agonist WIN 55212-2 to stimulate incorporation of [alpha-(32)P]azidoanilido-GTP into G(alpha) subunits in membranes. Photolabeled G proteins were either directly resolved using urea/SDS-polyacrylamide gel electrophoresis or first immunoprecipitated with specific antisera for different G(alpha) subunits before electrophoresis. Individual G(alpha) subunits were separated into distinct bands on a single gel and the amount of agonist-induced increase in radioactivity was quantified by densitometry. Stimulation of CB1 receptors by WIN 55212-2 resulted in the activation of a distinct pattern of at least five different G(ialpha)/G(oalpha) subunits in several brain regions. Furthermore, although the pattern of G proteins activated by WIN 55212-2 appeared to be similar across brain regions, slight differences were observed in both the percentage of increase and the amount of the individual G(alpha) subunits activated. Most importantly, the amount of WIN 55212-2 required to half-maximally activate individual G proteins in the cerebellum varied over a 30-fold range for different G(alpha) subunits. These results suggest that cannabinoid receptors activate multiple G proteins simultaneously in several brain regions and both the efficacy and potency of cannabinoid agonists to activate individual G(alpha) subunits may vary considerably.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779385

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  31 in total

1.  G-protein alpha subunit isoforms couple differentially to receptors that mediate presynaptic inhibition at rat hippocampal synapses.

Authors:  Alex J Straiker; Catherine R Borden; Jane M Sullivan
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

2.  Statistical Parametric Mapping reveals ligand and region-specific activation of G-proteins by CB1 receptors and non-CB1 sites in the 3D reconstructed mouse brain.

Authors:  P T Nguyen; D E Selley; L J Sim-Selley
Journal:  Neuroimage       Date:  2010-05-06       Impact factor: 6.556

Review 3.  Efficacy in CB1 receptor-mediated signal transduction.

Authors:  Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2004-08       Impact factor: 8.739

4.  Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Authors:  Lisa K Brents; Anna Gallus-Zawada; Anna Radominska-Pandya; Tamara Vasiljevik; Thomas E Prisinzano; William E Fantegrossi; Jeffery H Moran; Paul L Prather
Journal:  Biochem Pharmacol       Date:  2012-01-18       Impact factor: 5.858

Review 5.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

6.  AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Authors:  Kathryn A Seely; Lisa K Brents; Lirit N Franks; Maheswari Rajasekaran; Sarah M Zimmerman; William E Fantegrossi; Paul L Prather
Journal:  Neuropharmacology       Date:  2012-07-04       Impact factor: 5.250

7.  Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors.

Authors:  Jai Shankar K Yadlapalli; Benjamin M Ford; Amit Ketkar; Anqi Wan; Narasimha R Penthala; Robert L Eoff; Paul L Prather; Maxim Dobretsov; Peter A Crooks
Journal:  Pharmacol Res       Date:  2016-09-13       Impact factor: 7.658

Review 8.  New concepts in pharmacological efficacy at 7TM receptors: IUPHAR review 2.

Authors:  Terry Kenakin
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

9.  A putative 'pre-nervous' endocannabinoid system in early echinoderm development.

Authors:  G A Buznikov; L A Nikitina; V V Bezuglov; M E Y Francisco; G Boysen; I N Obispo-Peak; R E Peterson; E R Weiss; H Schuel; B R S Temple; A L Morrow; J M Lauder
Journal:  Dev Neurosci       Date:  2009-11-12       Impact factor: 2.984

10.  Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.

Authors:  Krishna C Chimalakonda; Kathryn A Seely; Stacie M Bratton; Lisa K Brents; Cindy L Moran; Gregory W Endres; Laura P James; Paul F Hollenberg; Paul L Prather; Anna Radominska-Pandya; Jeffery H Moran
Journal:  Drug Metab Dispos       Date:  2012-08-17       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.